市场见解

Universal Biosensors (ASX:UBI) share price up on “global first” 30-second COVID-19 test

This micro-cap biotech has big news for ASX investors today.
The post Universal Biosensors (ASX:UBI) share price up on “global first” 30-second COVID-19 test appeared first on The Motley Fool Australia. –

The Universal Biosensors Inc (ASX: UBI) share price is in the green after the company announced a licensing deal to commercialise a new rapid COVID-19 test.

Shares in the biotech are swapping hands for 89 cents at the time of writing, up 0.57%. Shortly after the market open, the share price jumped to an intraday high thus far of 94 cents. This is 6.8% higher than yesterday’s close.

Let’s take a look at the news driving positive investor sentiment today.

What is impacting the Universal Biosensors share price?

Universal Biosensors informed ASX investors that it has signed a deal with IQ Science Limited. The deal will commercialise a new rapid COVID-19 test.

The SARS-CoV-2 N-protein detection test will use the company’s electrochemical strip and device technology.

Initial internal validation work found the COVID-19 test can detect the virus within just 30 seconds.

Universal Biosensors has been working with IQ Science founder Dr Shalen Kumar on the technology for 6 months.

The licensing agreement is globally exclusive. Commercialisation fees will be paid either after the test gains regulatory approval, or when the test generates $1 million in sales.

Universal Biosensors will manage funding for the project and gaining all the regulatory approvals required to commercialise the test. If the test is not taken to the market within the next 5 years, the licence will become non-exclusive.

Management comment

Commenting on the COVID-19 test agreement, Universal Biosensors CEO John Sharman said:

The deal with IQ Science is an important breakthrough for UBI since it will be the first time our platform will use aptamers as a detection technique.

Aptamers are a next generation biorecognition element which when combined with our existing technology platform should allow us to detect and measure a large number of targets.

Based on what we know is available in the world today, a COVID-19 Test offering an accurate result within 30 seconds of the patient sample will be the first of its kind globally.

Universal Biosensors share price snapshot

The Universal Biosensors share price has surged by roughly 106% in the past 12 months. For perspective, the S&P/ASX 200 Index (ASX: XJO) is up by more than 11% over the same period.

The company has a market capitalisation of roughly $159 million based on its current share price.

The post Universal Biosensors (ASX:UBI) share price up on “global first” 30-second COVID-19 test appeared first on The Motley Fool Australia.

Should you invest $1,000 in Universal Biosensors right now?

Before you consider Universal Biosensors, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Universal Biosensors wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Could 2022 be a good year for the Westpac (ASX:WBC) share price?

Sonic (ASX:SHL) share price hits 52-week high amid COVID booster change

ASX 200 (ASX:XJO) midday update: AMP shoots higher, travel shares rise

What’s going on with the Inoviq (ASX:IIQ) share price today?

Why is the OncoSil Medical (ASX:OSL) share price surging 18% today?

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!